Ethical approval for multicenter cohort studies on drug exposure during pregnancy: A survey among members of the European Network of Teratology Information Services (ENTIS).

[1]  B. Stahl,et al.  Outcome of breastfed infants following post-partum methylergonovine treatment , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  A. Kayser,et al.  Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. , 2017, Reproductive toxicology.

[3]  A. Ornoy,et al.  Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. , 2016, The Journal of clinical psychiatry.

[4]  V. Rousson,et al.  Pregnancy outcome following maternal exposure to pregabalin may call for concern , 2016, Neurology.

[5]  D. Kennedy,et al.  Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. , 2015, British journal of clinical pharmacology.

[6]  T. Buclin,et al.  Pregnancy Outcome Following Maternal Exposure to Mirtazapine: A Multicenter, Prospective Study , 2015, Journal of clinical psychopharmacology.

[7]  B. Stahl,et al.  Colchicine use during breastfeeding. , 2015, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

[8]  D. Fletcher,et al.  Ethical procedures and patient consent differ in Europe , 2015, European journal of anaesthesiology.

[9]  G. Koren,et al.  Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort Study , 2014, Arthritis & rheumatology.

[10]  T. Buclin,et al.  Pregnancy outcome following maternal exposure to statins: a multicentre prospective study , 2013, BJOG : an international journal of obstetrics and gynaecology.

[11]  A. Møller.  Ethical requirements in Europe: different legislations, different traditions, the Danish perspective. , 2013, European journal of anaesthesiology.

[12]  M. Clementi,et al.  The Outcomes of Pregnancy in Women Exposed to the New Macrolides in the First Trimester , 2012, Drug Safety.

[13]  T. Buclin,et al.  Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study , 2012, Journal of clinical pharmacology.

[14]  T. Einarson,et al.  Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. , 2012, The Journal of clinical psychiatry.

[15]  T. Einarson,et al.  Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study , 2012, Journal of clinical pharmacology.

[16]  M. Clementi,et al.  Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services , 2012, American journal of medical genetics. Part A.

[17]  C. Schaefer.  Drug safety in pregnancy: Utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services , 2011, Congenital anomalies.

[18]  J. Polifka,et al.  Better data needed from pregnancy registries. , 2009, Birth defects research. Clinical and molecular teratology.

[19]  M. Clementi,et al.  Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. , 2008, British journal of clinical pharmacology.

[20]  Reinhard Meister,et al.  The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. , 2008, Reproductive toxicology.

[21]  M. Clementi,et al.  Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. , 2008, Reproductive toxicology.

[22]  T. Einarson,et al.  Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. , 2008, The American journal of psychiatry.

[23]  G. Koren,et al.  Providing information regarding exposures in pregnancy: a survey of North American Teratology Information Services. , 2008, Reproductive toxicology.

[24]  K. Dear,et al.  Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? , 2007, Internal medicine journal.

[25]  M. Clementi,et al.  Vitamin K antagonists and pregnancy outcome , 2006, Thrombosis and Haemostasis.

[26]  R. Meister,et al.  Post-marketing surveillance system for drugs in pregnancy--15 years experience of ENTIS. , 2005, Reproductive toxicology.

[27]  M. Clementi,et al.  Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. , 2005, The Journal of clinical psychiatry.

[28]  M. Clementi,et al.  Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. , 2005, Reproductive toxicology.

[29]  M. Clementi,et al.  The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study , 2005, Alimentary pharmacology & therapeutics.

[30]  Kathleen A. Johnson,et al.  Postmarketing surveillance for drug safety in pregnancy: the Organization of Teratology Information Services project. , 2004, Birth defects research. Part A, Clinical and molecular teratology.

[31]  H. Hearnshaw.  Comparison of requirements of research ethics committees in 11 European countries for a non-invasive interventional study , 2004, British medical journal.

[32]  R. K. Miller,et al.  Postmarketing surveillance for human teratogenicity: a model approach. , 2001, Teratology.

[33]  K. Jones,et al.  Selection bias in Teratology Information Service pregnancy outcome studies. , 2001, Teratology.